生物制剂在红皮病型银屑病中的应用

Use of Biologic Agents for the Treatment of Erythrodermic Psoriasis

红皮病型银屑病是一种重症银屑病类型,临床上表现为泛发的水肿性红斑,伴或不伴系统症状。红皮病型银屑病起病可以急骤、凶险,也可演变为一种慢性、持续性状态,治疗非常困难。目前对红皮病型银屑病治疗方案仅有病例和病例系列研究。近年研究发现肿瘤坏死因子拮抗剂、白介素17抗体、白介素23抗体等生物制剂在治疗红皮病型银屑病中也有很好的疗效和安全性。另外,还可以选择治疗药物联合应用。

Erythrodermic psoriasis is a severe variant of psoriasis characterized by diffused edematous erythema and occasional systemic symptoms. The course of erythrodermic psoriasis can be acute and critical or followed with a persistent chronic state that is difficult to manage. At present,there are only case reports and case series concerning the therapeutic options. Recent research indicated that tumor necrosis factor alpha antagonists and latest generation of biologic agents,such as monoclonal antibodies of Interleukin 17 and 23,were efficient and safe in treatment of severe erythrodermic psoriasis patients. In addition,drug combination is a potential therapy.